Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, NY, Dec. 02, 2024 (GLOBE NEWSWIRE) -- MeAI, a leading innovator in AI and DeSci, announces the listing of its native token, $MEAI, following a successful Initial Dex Offering (IDO). The...
-
Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
-
Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
-
The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder program TEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc...
-
The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program Tel Aviv, Israel / Vancouver, Canada, Dec. 01, 2023 (GLOBE...
-
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- ...
-
NEW YORK, NY, Oct. 10, 2023 (GLOBE NEWSWIRE) -- MeAI is proud to annouce their solutions to revolutionize self-Improvement and healthy living with AI and Blockchain technology. In the...
-
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. ...
-
TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and...